(Total Views: 614)
Posted On: 05/10/2019 8:53:12 PM
Post# of 30067
This is music to my ears. I was really afraid Kitov would give Coeptis the boot for failing to raise funds. Sounds like they still have faith that they can raise money.
“We look forward to the commercial launch in the U.S. by our commercialization partner, Coeptis Pharmaceuticals, which is planned for the fourth quarter of 2019.” stated Kitov CEO, Isaac Israel.
David Mehalick, Co-founder & Executive Vice President of Coeptis, said, “Consensi™ will substantially improve treatment for patients living with two highly prevalent chronic conditions, delivering improved clinical outcomes and enhanced economics for healthcare providers. We expect to have it widely available soon to the millions of Americans who can benefit from this combination treatment.”
The question is whether PsychoGenics will have similar patience or terminate our Eltoprazine license. Boy, a PR update would be helpful ...
“We look forward to the commercial launch in the U.S. by our commercialization partner, Coeptis Pharmaceuticals, which is planned for the fourth quarter of 2019.” stated Kitov CEO, Isaac Israel.
David Mehalick, Co-founder & Executive Vice President of Coeptis, said, “Consensi™ will substantially improve treatment for patients living with two highly prevalent chronic conditions, delivering improved clinical outcomes and enhanced economics for healthcare providers. We expect to have it widely available soon to the millions of Americans who can benefit from this combination treatment.”
The question is whether PsychoGenics will have similar patience or terminate our Eltoprazine license. Boy, a PR update would be helpful ...
(0)
(0)
